Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent sorafenib plus TACE in hepatocellular carcinoma
DRKS00012551Phase 2Completed
- Sponsor
- Universitätsmedizin Frankfurt
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Universitätsmedizin Frankfurt. Started Jul 2017; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on DRKS00012551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00012551.